Serum tumor biomarkers (such as CEA, CA19-9, CA125), released by tumor cells or immune cells in response to tumor growth, play an important function in clinical diagnosis, prognosis, and anti-drug surveillance, as well as in predicting therapeutic outcomes in NSCLC. This evidence concerns the gene MUC16 and neoplasm.